Cellectis (CLLS)

• Market cap: $314M
• 1 day: -0.95%
• 5 days: -4.28%
• 1 month: 7.93%
• 3 months: 128.47%
• 6 months: 154.47%
• Year to date: 72.93%
• 1 year: 33.76%
• 5 years: -84.62%
• 10 years: -90.79%
• Sector: Healthcare
• Industry: Biotechnology

About: Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Employees: 222

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

6% more capital invested

Capital invested by funds: $16.9M [Q1] → $17.8M (+$959K) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

2.59% less ownership

Funds ownership: 18.87% [Q1] → 16.28% (-2.59%) [Q2]

19% less funds holding

Funds holding: 27 [Q1] → 22 (-5) [Q2]

29% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 7

67% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 6